ASX:OPT

Email Alerts for:
ASX:OPT

Opthea (ASX:OPT) granted Chinese patent

27 Oct 2021 - Opthea (ASX:OPT) has been granted a Chinese patent covering its lead compound OPT-302.

Cue Energy (ASX:CUE) settles litigation: Aus shares close 1.5% higher

25 Sep 2020 - It has been a positive day of trade for the Australian share market. The ASX200 index rose in early trade, and tracked sideways for most of the day to close 1.5 per c…

Opthea (ASX:OPT) plans Nasdaq listing

25 Sep 2020 - Biopharmaceutical company Opthea (ASX:OPT) has revealed plans to list American depositary receipts on the Nasdaq index.

Filled jobs fall 0.1 per cent: Aus shares close 0.1% higher

10 Jun 2020 - The Australian share market fell at the open, but closed 0.1 per cent up at the end of trade. Filled jobs fell by 0.1 per cent and hours worked by 0.8 per cent betwee…

Opthea (ASX:OPT) reports positive trial results: Aus shares 0.5% higher at noon

10 Jun 2020 - The Australian share market opened lower but is now trading 0.5 per cent up at noon. Opthea (ASX:OPT) has reported positive Phase 2a trial results for its OPT-302 tre…

Opthea (ASX:OPT) Presentation, FNN Investor Event, February 2020, Sydney

10 Mar 2020 - Opthea (ASX:OPT) Managing Director and CEO, Dr Megan Baldwin presents on the company's large and growing market opportunity, the progress of its clinical program and …

Opthea (ASX:OPT) combatting macular degeneration

10 Mar 2020 - Opthea Limited (ASX:OPT) Managing Director and CEO, Dr Megan Baldwin talks about results from the company's lead drug candidate OPT-302, and new funding for further c…

Oil price volatility due to Midde East tensions: ASX poised to open higher

07 Jan 2020 - Tensions between the US and the Middle East continue to make investors wary as European and Asian shares ended lower. The ASX is poised to open higher this morning. O…

Opthea (ASX:OPT) raises $50 million in Institutional Placement

02 Dec 2019 - Biopharmaceutical company Opthea (ASX:OPT) today announced that the company has received commitments from sophisticated and institutional investors in Australia and t…

Opthea’s Patent Application Covering OPT-302 to be Granted by European Patent Office

30 Jul 2019 - Ophthalmic disease therapies company, Opthea (ASX:OPT) has today announced that the European Patent Office (EPO) intends to grant a patent covering one of Opthea's OP…

Opthea sees final patient for Phase 2b eye disease trial

15 May 2019 - Biopharmaceutical company Opthea (ASX:OPT) for eye disease has seen the final patient in the Company’s Phase 2b trial of OPT-302 for wet age-related macular degenerat…

Opthea completes patient recruitment ahead of schedule in Phase 2b Wet AMD clinical trial

14 Nov 2018 - Biotech company, Opthea (ASX:OPT) has announced that recruitment into the company's ongoing Phase 2b trial of (OPT-302) for wet age related macular degeneration is co…

Opthea doses first patients in Australia for phase 2a trial of OPT-302

17 Sep 2018 - Biotech company, Opthea (ASX:OPT) has successfully dosed the first patients in Australia as part of its Phase 2a clinical study.

Miners, banks, telcos losing ground: Aus shares 0.7% lower at noon

05 Sep 2018 - The ASX is tracking 0.7 per cent lower at noon. Miners, banks and telco stocks are all losing ground. Opthea (ASX:OPT) has received a positive interim review from th…

Opthea (ASX:OPT) tackling degenerative eye disease

30 May 2018 - Opthea Limited (ASX:OPT) Managing Director and CEO Dr Megan Baldwin talks about advances with the company's lead drug candidate OPT-302 in the treatment of wet age-re…

Opthea (ASX:OPT) Presentation, FNN Investor Event, May 2018, Sydney

30 May 2018 - Opthea Limited (ASX:OPT) Managing Director and CEO, Dr Megan Baldwin presents on the company's lead drug candidate OPT-302 for the treatment of wet age-related macula…

Opthea starts diabetes complication treatment trial

03 Jan 2018 - Opthea, (ASX:OPT) a biopharmaceutical company that focuses on developing treatments for eye diseases, has commenced a trial to test the safety and efficacy of its tre…

Horizontal finish: Aus shares close 0.08% lower

06 Jul 2017 - Horizontal finish: Aus shares close 0.08% lower. Touchcorp (ASX:TCH) has announced all of its shares have now been transferred to the newly incorporated, Afterpay Tou…

Opthea receives notice of allowance for key US patent

06 Jul 2017 - Opthea (ASX:OPT) announces it has received a Notice of Allowance from the US Patent and Trade Mark Office for its OPT-302, used for the treatment of eye diseases.

Opthea (ASX:OPT) talks treatment of eye disease

24 May 2017 - Opthea Limited (ASX:OPT) Managing Director, Dr Megan Baldwin, discusses the company’s lead drug candidate OPT-302 for the treatment of macular degeneration.

Opthea (ASX:OPT): Presentation, CEO Sessions, Sydney

24 May 2017 - Opthea Limited (ASX:OPT) Managing Director Dr Megan Baldwin presents at the ASX CEO Sessions in Sydney.

Opthea completes patient enrolment

30 Mar 2016 - Opthea Limited (ASX:OPT) completes patient enrolment in its ongoing Phase 1 dose escalation clinical trial of OPT-302.

Opthea Limited: Presentation, CEO Sessions Sydney

24 Feb 2016 - Opthea Limited (ASX:OPT) CEO and Managing Director, Dr Megan Baldwin presents at the CEO Sessions in Sydney.

Opthea makes ophthalmology the focus

24 Feb 2016 - Opthea Limited (ASX:OPT) CEO and Managing Director, Dr Megan Baldwin discusses the company’s recent name change and focus on eye-disease treatment.